TY - JOUR
T1 - Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL
T2 - Impact of imatinib on relapse and survival
AU - Burke, M. J.
AU - Trotz, B.
AU - Luo, X.
AU - Baker, K. S.
AU - Weisdorf, D. J.
AU - Wagner, J. E.
AU - Verneris, M. R.
N1 - Funding Information:
This work was supported by the Children’s Cancer Research.
PY - 2009
Y1 - 2009
N2 - The utility of imatinib in either the pre- or post-transplant period for Ph chromosome-positive (Ph+) ALL is uncertain. In addition, there have been recent concerns regarding imatinib and cardiac toxicity. We investigated the outcome of 32 patients with Ph+ ALL who received an allo-hematopoietic cell transplant (HCT) at the University of Minnesota between 1999 and 2006. The median age at HCT was 21.9 years (range: 2.8-55.2). All patients were conditioned with CY and TBI. GVHD prophylaxis was CsA based. Of the 32 patients, 15 received imatinib therapy pre- or post-HCT (imatinib group) and 17 patients received either no imatinib (n=11) or only after relapse (n=6) (non-imatinib group). Overall survival, relapse-free survival and relapse at 2 years was 61, 67 and 13% for the imatinib group as compared with 41, 35 and 35% for the non-imatinib group (P=0.19, 0.12 and 0.20, respectively). Cardiac toxicity and TRM at 2 years were similar between groups. Thus, patients treated with imatinib in either the pre- or post-transplant setting had trends toward improved outcomes and no increase in cardiac toxicity. We suggest that imatinib be included in the peri-transplant management of all patients with Ph+ ALL.
AB - The utility of imatinib in either the pre- or post-transplant period for Ph chromosome-positive (Ph+) ALL is uncertain. In addition, there have been recent concerns regarding imatinib and cardiac toxicity. We investigated the outcome of 32 patients with Ph+ ALL who received an allo-hematopoietic cell transplant (HCT) at the University of Minnesota between 1999 and 2006. The median age at HCT was 21.9 years (range: 2.8-55.2). All patients were conditioned with CY and TBI. GVHD prophylaxis was CsA based. Of the 32 patients, 15 received imatinib therapy pre- or post-HCT (imatinib group) and 17 patients received either no imatinib (n=11) or only after relapse (n=6) (non-imatinib group). Overall survival, relapse-free survival and relapse at 2 years was 61, 67 and 13% for the imatinib group as compared with 41, 35 and 35% for the non-imatinib group (P=0.19, 0.12 and 0.20, respectively). Cardiac toxicity and TRM at 2 years were similar between groups. Thus, patients treated with imatinib in either the pre- or post-transplant setting had trends toward improved outcomes and no increase in cardiac toxicity. We suggest that imatinib be included in the peri-transplant management of all patients with Ph+ ALL.
UR - http://www.scopus.com/inward/record.url?scp=59549085066&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=59549085066&partnerID=8YFLogxK
U2 - 10.1038/bmt.2008.296
DO - 10.1038/bmt.2008.296
M3 - Article
C2 - 18776928
AN - SCOPUS:59549085066
SN - 0268-3369
VL - 43
SP - 107
EP - 113
JO - Bone marrow transplantation
JF - Bone marrow transplantation
IS - 2
ER -